Literature DB >> 14767871

Apolipoprotein E genotype and changes in serum lipids and maximal oxygen uptake with exercise training.

Paul D Thompson1, Gregory J Tsongalis, Richard L Seip, Cherie Bilbie, Mary Miles, Robert Zoeller, Paul Visich, Paul Gordon, Theodore J Angelopoulos, Linda Pescatello, Linda Bausserman, Niall Moyna.   

Abstract

Physical activity improves lipid levels by altering triglyceride (TG) metabolism. Apolipoprotein E (Apo E) facilitates TG clearance by mediating lipoprotein binding to hepatic receptors, but Apo E also has less defined roles in skeletal muscle and nervous tissue. This study examined if variants in Apo E genotype affect the lipid and physiologic response to exercise training. Seven centers genetically screened 566 individuals to recruit 120 subjects into 6 gender-specific cohorts equal for the most common Apo E genotypes: E2/3, E3/3, and E3/4. Anthropometics, exercise capacity (Vo(2)max), serum lipids, and post heparin (PH) plasma lipase activities were measured before and after 6 months of supervised exercise training. Difference in the response (Delta) to training among the Apo E genotypes was the primary outcome variable. Differences in pretraining serum lipids among the Apo E genotypes mimicked those observed in population studies: TGs were slightly higher in E2/3 subjects, whereas low-density lipoprotein (LDL)-cholesterol (C) was lower (P = not significant [NS] ). TGs decreased 11% with training for the entire cohort (P <.0001) and 7%, 12%, and 14% for the Apo E 2/3, 3/3 and 3/4 groups, respectively (P = NS for Delta). LDL-C did not change in the entire cohort, but decreased slightly in the 2/3 and 3/3 subjects and increased 4% in the 3/4 group (P = NS for Delta). High-density lipoprotein (HDL)-C increased 2% for the entire cohort (P =.06) due to a 6% increase in the 3/3 group (P =.07 for Delta). Total cholesterol (TC)/HDL and LDL/HDL decreased with training in the 2/3 and 3/3 groups, but increased in the 3/4 subjects and these responses differed among the genotypes (P <.05 for Delta). Vo(2)max increased 9% to 10% for the entire cohort, but only 5% in the 3/3 subjects versus 13% in the 2/3 and 3/4 groups and these differences were significantly different among the genotypes (P <.01 for Delta). This is the first prospective study to demonstrate that the serum lipid response to exercise training differs by Apo E genotype in a pattern consistent with known metabolic differences among the variants. Surprisingly, Apo E genotype also affected the increase in aerobic capacity produced by exercise training possibly via undefined effects on nerve and skeletal muscle function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767871     DOI: 10.1016/j.metabol.2003.09.010

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  18 in total

Review 1.  Genes and human elite athletic performance.

Authors:  Daniel G Macarthur; Kathryn N North
Journal:  Hum Genet       Date:  2005-02-22       Impact factor: 4.132

Review 2.  Genomics and genetics in the biology of adaptation to exercise.

Authors:  Claude Bouchard; Tuomo Rankinen; James A Timmons
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

3.  Interactive effects of APOE haplotype, sex, and exercise on postheparin plasma lipase activities.

Authors:  Richard L Seip; Robert F Zoeller; Theodore J Angelopoulos; James Salonia; Cherie Bilbie; Niall M Moyna; Mary P Miles; Paul S Visich; Linda S Pescatello; Paul M Gordon; Gregory J Tsongalis; Linda Bausserman; Paul D Thompson
Journal:  J Appl Physiol (1985)       Date:  2011-01-20

4.  APOEε4 impacts up-regulation of brain-derived neurotrophic factor after a six-month stretch and aerobic exercise intervention in mild cognitively impaired elderly African Americans: A pilot study.

Authors:  Joanne S Allard; Oyonumo Ntekim; Steven P Johnson; Julius S Ngwa; Vernon Bond; Dynell Pinder; Richard F Gillum; Thomas V Fungwe; John Kwagyan; Thomas O Obisesan
Journal:  Exp Gerontol       Date:  2016-11-15       Impact factor: 4.032

5.  Exercise, Physical Activity, and Cardiometabolic Health: Pathophysiologic Insights.

Authors:  Matthew J Belanger; Prashant Rao; Jeremy M Robbins
Journal:  Cardiol Rev       Date:  2022 May-Jun 01       Impact factor: 3.109

6.  Apolipoprotein E genotype and sex influence C-reactive protein levels regardless of exercise training status.

Authors:  Theodore J Angelopoulos; Mary P Miles; Joshua Lowndes; Stephen A Sivo; Richard L Seip; Linda S Pescatello; Robert F Zoeller; Paul S Visich; Paul M Gordon; Niall M Moyna; Paul D Thompson
Journal:  Metabolism       Date:  2008-09       Impact factor: 8.694

7.  Relationships between exercise-induced reductions in thigh intermuscular adipose tissue, changes in lipoprotein particle size, and visceral adiposity.

Authors:  Michael T Durheim; Cris A Slentz; Lori A Bateman; Stephanie K Mabe; William E Kraus
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-10       Impact factor: 4.310

8.  Do age and baseline LDL cholesterol levels determine the effect of regular exercise on plasma lipoprotein cholesterol and apolipoprotein B levels?

Authors:  Theodore J Angelopoulos; Stephen A Sivo; George A Kyriazis; Jonathan D Caplan; Robert F Zoeller; Joshua Lowndes; Richard L Seip; Paul D Thompson
Journal:  Eur J Appl Physiol       Date:  2007-08-14       Impact factor: 3.078

9.  Similarity of polygenic profiles limits the potential for elite human physical performance.

Authors:  Alun G Williams; Jonathan P Folland
Journal:  J Physiol       Date:  2007-09-27       Impact factor: 5.182

10.  The effects of exercise on the lipoprotein subclass profile: A meta-analysis of 10 interventions.

Authors:  Mark A Sarzynski; Jeffrey Burton; Tuomo Rankinen; Steven N Blair; Timothy S Church; Jean-Pierre Després; James M Hagberg; Rian Landers-Ramos; Arthur S Leon; Catherine R Mikus; D C Rao; Richard L Seip; James S Skinner; Cris A Slentz; Paul D Thompson; Kenneth R Wilund; William E Kraus; Claude Bouchard
Journal:  Atherosclerosis       Date:  2015-10-17       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.